| HOME >> BIOLOGY >> TECHNOLOGY |
- New test provides laboratory-quality results in physician's office -
MADISON, N.J., May 8 /PRNewswire-FirstCall/ -- Enterix Inc., a wholly-owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced the availability of the InSure(R) Quik F I T(TM) fecal immunochemical test, a point-of-care version of the company's lab-based InSure(R) FIT(TM) test, that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test.
The availability of the CLIA-waived InSure Quik F I T test is intended to help physicians increase patient compliance with an annual colorectal cancer screening test. Although colorectal cancer is the second leading cause of cancer in the U.S.(1), screening rates for the disease are low compared to screenings for cervical and prostate cancers(2),(3), and colorectal cancer claims the lives of up to 50,000 Americans each year.(1) The American Cancer Society (ACS) recommends yearly screening with a fecal occult blood test (FOBT), such as the fecal immunochemical test (FIT) as an alternative to colonoscopy every ten years, for people 50 and older at average risk, to improve rates of early detection of this disease, which is largely treatable if detected in its early stages.
Studies have shown that the InSure FIT test is highly sensitive for
detecting blood in or around the stool. In a study of patients who were at
average risk, high risk or had no symptoms at all, InSure FIT was found to
have 33% greater sensitivity for colorectal cancer than a leading
guaiac-based FOBT screening test.(4) The InSure Quik F I T test uses the
same patient-friendly blue brush collection method as the InSure FIT and is
considered substantially equivalent to the InSure FIT test.
'/>"/>
| SOURCE Quest Diagnostics Copyright©2008 PR Newswire. All rights reserved |